Sign in

UiPath, Inc. PATH

Price 18.0 USD
as of 2026-09-03
66/100
Mixed
Quality60
Growth66
Balance-sheet strength92
Valuation41
Momentum81
Income50

Composite 66/100; the shares have moved about 60% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Valuation ranks 41/100 — a slight mark against it.

Case for

Balance-sheet strength ranks 92/100 — a strong point in its favour. Momentum ranks 81/100 — a strong point in its favour. Growth ranks 66/100 — a moderate point in its favour.

Case against

Valuation ranks 41/100 — a slight mark against it.

What the company does UiPath provides an integrated automation platform combining RPA, AI agents, process orchestration, and governance for enterprises across financial services, healthcare, manufacturing, retail, and public sectors.

Key financials UiPath posts strong margins (gross 83.1%, operating 7.3%, net 19.6%) and growth (revenue 17.3%, EPS 105.7%). ROE is 18.2%, ROA 2.4%, and ROCE 6.7%. Leverage is low (debt/equity 0.04) with net cash and a current ratio of 2.31.

Stock health Quality and momentum scores trail peers (Quality 52.5, Momentum 47.2), though Strength is high (93.6). The stock is down 36.37% from its 52-week high and has a 1-day gain of 2.06%.

Price vs fair value The stock trades at a discount of 10.00% to our fair-value estimate of 13.88 and a discount of 4.98% to the analyst 12-month target of 13.25. - Recent articles highlight UiPath’s decline amid market improvement and question whether it remains below fair value after a rebound (Zacks, Simply Wall St.). - Comparisons to peers like Marvell and Snowflake suggest competitive pressures in AI automation (Motley Fool). - Simply Wall St. notes the stock could still be below fair value despite an 80% slump.

Looking forward Forward P/E of 13.64 and PEG of 0.42 suggest valuation support, while revenue growth of 17.3% and strong FCF yield of 7.8% indicate operational resilience. Analysts’ 12-month target implies ~5% upside from the current price.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.